N. Daver

M. Konopleva, H. Kantarjian, Xuelin Huang, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extramedullary B lymphoblastic leukemia/lymphoma (B-ALL/B-LBL): a diagnostic challenge.

N. Daver, S. O'brien, N. Pemmaraju, 2014, Clinical lymphoma, myeloma & leukemia.

An Exciting New Era in the Treatment of Myeloproliferative Neoplasms

N. Daver, R. Assi, 2016 .

Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients.

M. Konopleva, M. Andreeff, H. Kantarjian, 2014 .

Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions.

N. Daver, A. Maiti, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Y. Qi, B. Ebert, Xiaoping Su, 2022, Blood cancer journal.

Development of TP53 mutations over the course of therapy for acute myeloid leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2021, American journal of hematology.

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

M. Konopleva, M. Andreeff, K. Bhalla, 2019, Journal of Clinical Oncology.

Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin

M. Konopleva, H. Kantarjian, K. Patel, 2020, American journal of hematology.

Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.

M. Konopleva, M. Andreeff, K. Bhalla, 2020, Blood cancer discovery.

Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

R. Collins, M. Konopleva, Z. Estrov, 2016 .

Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations

Z. Estrov, H. Kantarjian, J. Cortes, 2014 .

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA.

D. Musher, N. Daver, S. Shelburne, 2008, The Journal of infection.

Dorsal column myelopathy after intrathecal chemotherapy for leukemia

G. Fuller, M. Konopleva, H. Kantarjian, 2017, American journal of hematology.

Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, Leukemia & lymphoma.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Leukemia research.

Romiplostim: Therapeutic Value in Chronic Immune Thrombocytopenic Purpura

N. Daver, L. Rice, M. Tanaka, 2010 .

Efficacy of Novel Glutaminase Inhibitor CB-839 in Acute Myeloid Leukemia

J. Velez, Y. Qi, M. Konopleva, 2014 .

Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia

Koichi Takahashi, E. Jabbour, N. Daver, 2016, American journal of hematology.

Antibody-Drug Conjugates in Myeloid Leukemias.

N. Daver, N. Pemmaraju, Jayastu Senapati, 2022, Cancer journal.

Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis.

G. Garcia-Manero, N. Daver, A. Wei, 2022, Clinical lymphoma, myeloma & leukemia.

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Leukemia & lymphoma.

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors

O. Frankfurt, N. Daver, J. Altman, 2022, American journal of hematology.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

J. Welch, M. Konopleva, M. Andreeff, 2020, Haematologica.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

Is There an Optimal Conditioning for Older Patients with AML Receiving Allogeneic Hematopoietic Cell Transplantation?

M. Konopleva, N. Daver, U. Popat, 2019, Blood.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

P. Vyas, C. Takimoto, S. Kambhampati, 2020 .

Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, S. Colla, H. Kantarjian, 2018, Blood.

Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2018, Blood.

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Influence of IDH on FLT3-ITD status in newly diagnosed AML

H. Kantarjian, F. Ravandi, N. Daver, 2017, Leukemia.

Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group.

M. Andreeff, H. Kantarjian, J. Cortes, 2017, Blood advances.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case–control study

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2013, American journal of hematology.

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

M. Konopleva, K. Rezvani, S. Parmar, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome

M. Konopleva, K. Rezvani, H. Kantarjian, 2018, Clinical lymphoma, myeloma & leukemia.

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Andrew T Nguyen, B. Ebert, Jianhua Zhang, 2022, Blood.

Interim Results of the Phase I/II Study of the Ponatinib, Venetoclax and Dexamethasone for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, T. Kadia, F. Ravandi, 2020 .

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

M. Konopleva, H. Kantarjian, J. Cortes, 2020 .

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

N. Daver, M. Levis, J. Altman, 2021, Blood.

TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity

H. Kantarjian, N. Daver, A. Wei, 2022, Cancer.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.

P. Vyas, R. Larson, S. Kambhampati, 2022, Journal of Clinical Oncology.

Myelopathy following intrathecal chemotherapy in adults: a single institution experience

H. Kantarjian, J. Cortes, N. Daver, 2015, Journal of Neuro-Oncology.

Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Cancer.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

H. Kantarjian, J. Cortes, T. Manshouri, 2015, Leukemia research.

Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2015, Cancer.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2019, Blood.

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Abstract LB-222: Polyfunctionality determined by single-cell proteomics of bone marrow-derived CD4 T cells from patients with acute myeloid leukemia identifies patients responding to anti-PD-1-based therapy and discovers profound T cell defect in mutant TP53 disease

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, Clinical Research (Excluding Clinical Trials).

Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Triple combination targeting methyltransferase, BCL‐2, and PD‐1 facilitates antileukemia responses in acute myeloid leukemia

M. Konopleva, N. Daver, C. Dinardo, 2022, Cancer.

Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib

M. Konopleva, M. Andreeff, H. Kantarjian, 2019, American journal of hematology.

Targeting FLT3 mutations in AML: review of current knowledge and evidence

R. Schlenk, N. Russell, N. Daver, 2019, Leukemia.

Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Molecular targets for therapy Targeting FLT 3 mutations in AML : review of current knowledge and evidence

R. Schlenk, N. Russell, N. Daver, 2019 .

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions

M. Konopleva, N. Daver, C. Dinardo, 2020, Frontiers in Oncology.

Secondary mutations as mediators of resistance to targeted therapy in leukemia.

M. Konopleva, H. Kantarjian, K. Patel, 2015, Blood.

Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, G. Martinelli, 2021, Frontiers in Oncology.

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.

M. Konopleva, T. Kadia, F. Ravandi, 2020, Cancer discovery.

Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Philip R. Cohen, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients

Daniel Patrick Smith, N. Ajami, J. Petrosino, 2017, Genome Medicine.

Treating Leukemia in the Time of COVID-19

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Acta Haematologica.

MDM2 inhibition: an important step forward in cancer therapy

M. Konopleva, M. Andreeff, G. Martinelli, 2020, Leukemia.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

P. Hwu, K. Rezvani, E. Shpall, 2018, Nature Reviews Clinical Oncology.

Primary gastric chorioadenocarcinoma: a needle in a haystack

N. Daver, T. Hayes, A. Shastri, 2011, Rare tumors.

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, The Lancet. Haematology.

Acute myeloid leukemia: current progress and future directions

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood Cancer Journal.

Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia.

N. Daver, Megan Wiese, 2018, The American journal of managed care.

Frontline treatment of acute myeloid leukemia in adults.

M. Konopleva, H. Kantarjian, J. Cortes, 2017, Critical reviews in oncology/hematology.

P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse‐free survival

M. Konopleva, H. Kantarjian, M. Routbort, 2018, American journal of hematology.

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022 .

Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes

Chenyue W. Hu, M. Konopleva, A. Qutub, 2021, Frontiers in Oncology.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

M. Protopopova, R. DePinho, M. Konopleva, 2018, Nature Medicine.

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

M. Dawson, M. Tallman, G. Borthakur, 2017 .

Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia

G. Garcia-Manero, T. Kadia, N. Daver, 2021, Leukemia.

Flt3 in aml

F. Ravandi, N. Daver, 2015 .

Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

N. Daver, C. Dinardo, C. Zhang, 2023, Expert opinion on investigational drugs.

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, American journal of hematology.

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

N. Daver, M. Subklewe, V. Bücklein, 2021, Leukemia.

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Hannah C. Beird, P. Sharma, K. Tomczak, 2021, Nature Communications.

Targeting Immune Checkpoints in Hematologic Malignancies

E. Mittendorf, N. Daver, G. Alatrash, 2016, Pharmacological Reviews.

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

M. Konopleva, M. Andreeff, S. Paolini, 2022, Blood.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Cancer.

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndrome

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2021, British journal of haematology.

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

H. Kantarjian, S. Verstovsek, E. Jabbour, 2019, Leukemia & lymphoma.

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based Therapy

Michael R. Green, P. Sharma, K. Tomczak, 2020, bioRxiv.

Phase II Study of Prophylactic Non-Irradiated Granulocyte Transfusions in AML Patients Receiving Induction Chemotherapy

Fern, H. Kantarjian, T. Kadia, 2017 .

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Z. Ju, M. Konopleva, F. Meric-Bernstam, 2023, Nature Medicine.

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

J. Welch, M. Konopleva, Z. Estrov, 2020, The Lancet. Haematology.

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

M. Konopleva, J. Cortes, T. Kadia, 2021, Journal of Hematology & Oncology.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Jing Wang, M. Konopleva, M. Andreeff, 2019, Haematologica.

Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, F. Ravandi, 2018, Hematological oncology.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)

Y. Qi, B. Ebert, Xiaoping Su, 2022, Blood Cancer Journal.

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Blood.

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

P. Sharma, J. Allison, H. Kantarjian, 2018, Leukemia.

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

H. Kantarjian, S. Verstovsek, F. Ravandi, 2012, Clinical Cancer Research.

Hemophagocytic Lymphohistiocytosis in the Cancer Patient

N. Daver, O. Idowu, Jeannee Campbell, 2019, Oncologic Critical Care.

Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition.

N. Daver, A. Fathi, Anita Koshy, 2020, Best practice & research. Clinical haematology.

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2015, American journal of hematology.

FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, American journal of hematology.

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Clinical and molecular characterization of myeloid sarcoma without medullary leukemia

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Leukemia & lymphoma.

Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, K. Patel, 2023, Cancer.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Novel Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia – A Focus on Emerging Monoclonal Antibodies

N. Daver, S. O'brien, 2013, Current Hematologic Malignancy Reports.

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

P. Vyas, C. Craddock, R. Majeti, 2022, Cancer discovery.

Harnessing Apoptosis in AML.

M. Konopleva, N. Daver, C. Dinardo, 2021, Clinical lymphoma, myeloma & leukemia.

Harnessing Apoptosis in AML.

M. Konopleva, N. Daver, C. Dinardo, 2020, Clinical lymphoma, myeloma & leukemia.

Effective therapy of AML with RUNX1 mutation by co-treatment with inhibitors of protein translation and BCL2.

Y. Qi, K. Bhalla, X. Su, 2021, Blood.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Blood advances.

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Leukemia.

Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19

Sheeba J. Sujit, K. Brock, G. Gladish, 2022, Cancers.

Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS‐mutant Acute Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Clinical lymphoma, myeloma & leukemia.

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Post‐transplantation donor‐derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis

E. Shpall, N. Daver, C. Dinardo, 2021, American journal of hematology.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood Cancer Journal.

Malignancy-associated haemophagocytic lymphohistiocytosis in adults.

H. Kantarjian, N. Daver, 2017, The Lancet. Oncology.

Hemophagocytic lymphohistiocytosis in adults: An under recognized entity

Z. Estrov, H. Kantarjian, N. Daver, 2016, BBA clinical.

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, Blood.

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

H. Einsele, M. Konopleva, H. Kantarjian, 2018, American journal of hematology.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

M. Konopleva, Z. Estrov, Jianhua Zhang, 2016, Oncotarget.

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2023, Blood reviews.

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood advances.

Immunotherapy in Acute Myeloid Leukemia: Where We Stand

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.

P. Sharma, F. Ravandi, N. Daver, 2017, Advances in experimental medicine and biology.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011, Clinical lymphoma, myeloma & leukemia.

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

J. Issa, W. Chung, H. Kantarjian, 2013 .

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021 .

Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

E. Estey, M. Konopleva, Z. Estrov, 2017, Blood.

Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients.

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

The changing face of acute myeloid leukemia therapeutics in the elderly population

J. Cortes, N. Daver, 2015, South Asian Journal of Cancer.

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, Blood advances.

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2019, Blood.

Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Blood.

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

M. Konopleva, M. Andreeff, S. Paolini, 2019, Blood.

From DNA Sequencing to Clinical Trials: Finding New Targeted Drugs for Acute Myeloid Leukemia

N. Daver, M. Yilmaz, 2019, Drugs.

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia

M. Konopleva, N. Daver, V. Ruvolo, 2018, American journal of hematology.

Pernicious anemia with spuriously normal vitamin B12 level might be misdiagnosed as myelodysplastic syndrome.

G. Borthakur, N. Daver, T. H. Oo, 2014, Clinical lymphoma, myeloma & leukemia.

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

P. Vyas, R. Larson, C. Takimoto, 2021 .

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Z. Estrov, T. Kadia, G. Borthakur, 2018, Leukemia.

Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword.

N. Daver, B. Oran, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors

H. Kantarjian, F. Ravandi, N. Daver, 2017, Current opinion in hematology.

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology.

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Z. Estrov, H. Kantarjian, N. Daver, 2016 .

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Z. Estrov, H. Kantarjian, N. Daver, 2014 .

LLM Abstracts, AJH, V96 S1

Trisha, P. Vyas, G. Garcia-Manero, 2021, American Journal of Hematology.

Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial

M. Andreeff, N. Daver, V. Ruvolo, 2018, Haematologica.

AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies.

P. Vyas, H. Kantarjian, T. Kadia, 2022, Clinical lymphoma, myeloma & leukemia.

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood cancer journal.

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

M. Konopleva, G. Gaidano, H. Kantarjian, 2021, Blood.

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-Day Decitabine with Venetoclax Versus Intensive Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia: A Propensity Score Matched Analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Blood.

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia

H. Kantarjian, J. Cortes, K. Patel, 2020, Blood Cancer Journal.

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need.

M. Konopleva, H. Kantarjian, A. Lane, 2022, Blood.

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Vyas, M. Konopleva, G. Gaidano, 2022, Blood.

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2021, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2021, Blood cancer discovery.

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

M. Konopleva, M. Andreeff, K. Bhalla, 2022, Blood advances.

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Annals of Hematology.

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML)

Koichi Takahashi, N. Daver, C. Dinardo, 2020 .

A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies

M. Konopleva, H. Kantarjian, N. Daver, 2018, Blood.

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2020 .

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

M. Konopleva, M. Andreeff, G. Martinelli, 2017 .

Role of MSC-derived galectin 3 in the AML microenvironment.

M. Andreeff, E. Shpall, N. Daver, 2018, Biochimica et biophysica acta. Molecular cell research.

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

T. Kadia, N. Daver, H. Abbas, 2019, Cancer management and research.

Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

H. Kantarjian, F. Ravandi, N. Daver, 2019, Therapeutic advances in hematology.

CMAR_A_177894 8817..8828

T. Kadia, N. Daver, H. Abbas, 2019 .

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML.

M. Konopleva, H. Kantarjian, J. Cortes, 2020, Blood advances.

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

F. Ravandi, N. Daver, S. Venugopal, 2021, Blood Cancer Journal.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.

C. Mullighan, M. Konopleva, H. Kantarjian, 2020, The Lancet. Haematology.

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Haematologica.

A Phase I dose‐escalation study of DCLL9718S, an antibody‐drug conjugate targeting C‐type lectin‐like molecule‐1 (CLL‐1) in patients with acute myeloid leukemia

Connie Y. C. Ma, N. Daver, K. Yee, 2021, American journal of hematology.

Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study

P. Sharma, M. Konopleva, Z. Estrov, 2018, Blood.

Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial

P. Thall, K. Rezvani, D. Marin, 2021, Blood.

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Cancer.

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2021, Haematologica.

Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

M. Konopleva, Z. Estrov, M. Andreeff, 2020 .

Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2020, Leukemia.

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

G. Garcia-Manero, T. Kadia, F. Ravandi, 2021, Blood.

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Blood.

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia

P. Vyas, N. Daver, A. Wei, 2021, Blood.

A phase 1b/2 study of azacitidine with PD‐L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2021, Cancer.

Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2020 .

A phase Ib/II study of the CD123-targeting antibody-drug conjugate IMGN632 as monotherapy or in combination with venetoclax and/or azacitidine for patients with CD123-positive acute myeloid leukemia.

N. Daver, D. DeAngelo, E. Wang, 2020 .

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.

P. Sharma, M. Konopleva, Z. Estrov, 2019, The Lancet. Haematology.

ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial

M. Konopleva, K. Patel, D. Kipp, 2022, Blood.

Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Cancer.

Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy

M. Konopleva, T. Kadia, F. Ravandi, 2022, Blood advances.

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

V. Baladandayuthapani, H. Kantarjian, G. Garcia-Manero, 2015, Clinical lymphoma, myeloma & leukemia.

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

J. Issa, W. Chung, H. Kantarjian, 2017, Cancer.

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Leukemia.

Checkpoint Blockade + Chemotherapy: the Right Combination for AML?

J. Allison, N. Daver, J. Mancuso, 2021, Blood cancer discovery.

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis.

M. Konopleva, Z. Estrov, G. Garcia-Manero, 2021, Blood Advances.

Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data

P. A. Futreal, S. Ogawa, Jianhua Zhang, 2018, Blood.

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

M. Konopleva, G. Garcia-Manero, E. Shpall, 2022, Journal of Hematology & Oncology.

A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.

M. Konopleva, A. Lane, G. Martinelli, 2020 .

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study

I. Flinn, P. Vyas, S. Kambhampati, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Combination of Ruxolitinib (RUX) with Decitabine (DAC) in Patients (Pts) with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Interim Report of a Phase I/II Trial

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Decitabine therapy for myeloproliferative neoplasm in accelerated (MPN-AP) or blastic (acute myeloid leukemia; MPN-AML) phase.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis.

B. Ebert, A. Nagler, S. Nikiforow, 2021, Blood.

Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, The Lancet. Haematology.

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2020, Leukemia.

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2015, Leukemia.

Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome

M. Konopleva, M. Andreeff, H. Kantarjian, 2017, Haematologica.

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Z. Estrov, S. Colla, H. Kantarjian, 2017, American journal of hematology.

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

M. Konopleva, Z. Estrov, H. Kantarjian, 2020 .

Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and Decitabine

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

M. Konopleva, M. Andreeff, K. Bhalla, 2020 .

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

H. Kantarjian, G. Garcia-Manero, M. Routbort, 2020, bioRxiv.

Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy

K. Do, M. Konopleva, H. Kantarjian, 2020, American journal of hematology.

Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2017, Cancer.

Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients

M. Konopleva, M. Andreeff, H. Kantarjian, 2020, American journal of hematology.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2018, American journal of hematology.

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

H. Kantarjian, J. Cortes, F. Ravandi, 2016, Expert review of hematology.

Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, American journal of hematology.

Abstract CT162: Addition of parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis

N. Daver, U. Borate, G. Hobbs, 2021, Clinical Trials.

Sotatercept (ACE-011) for Anemia of Myelofibrosis: A Phase 2 Study

Z. Estrov, M. Andreeff, H. Kantarjian, 2020 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase II trial of cladribine and low-dose AraC alternating with decitabine in older patients with AML.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Unique case of ANCA-negative pauci-immune necrotizing glomerulonephritis with diffuse alveolar hemorrhage, potentially associated with midostaurin

N. Daver, W. Glass, Jaya Kala, 2020, CEN Case Reports.

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML

R. Davis, K. Baggerly, G. Sauvageau, 2021, Journal for ImmunoTherapy of Cancer.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.

H. Kantarjian, F. Ravandi, N. Daver, 2013, Clinical lymphoma, myeloma & leukemia.

Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis

N. Daver, R. Chan, G. Ramsingh, 2023, Journal of Hematology & Oncology.

Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia

G. Garcia-Manero, S. Verstovsek, F. Ravandi, 2020, British journal of haematology.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, International Journal of Hematology.

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

61st Annual Conference of Indian Society of Hematology & Blood Transfusion (ISHBT) November 2020

Marina, M. Andreeff, H. Kantarjian, 2020, Indian Journal of Hematology and Blood Transfusion.

A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B‐cell acute lymphoblastic leukaemia

M. Konopleva, H. Kantarjian, J. Cortes, 2018, British journal of haematology.

A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Cancer.

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML

M. Konopleva, J. Smaill, N. Daver, 2016 .

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018 .

Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase

M. Konopleva, H. Kantarjian, J. Cortes, 2017 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.

Z. Estrov, K. Bhalla, H. Kantarjian, 2018, Blood.

Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

N. Daver, U. Borate, G. Hobbs, 2022, Blood.

Phase-2 Study of Sotatercept (ACE-011) in Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia

H. Kantarjian, S. Verstovsek, E. Jabbour, 2016 .

Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis

Z. Estrov, M. Andreeff, H. Kantarjian, 2021, Blood.

The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

Guillermo Garcia-Manero, Angela Teng, H. Kantarjian, 2015, Leukemia & lymphoma.

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes

M. Konopleva, G. Garcia-Manero, J. Cortes, 2020, American journal of hematology.

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2019, Blood.

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Leukemia research.

Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

A Bayesian hierarchical monitoring design for phase II cancer clinical trials: Incorporating information on response duration into monitoring rules

Jian Wang, N. Daver, J. Ning, 2021, Statistics in medicine.

Checkpoint Expression By Acute Myeloid Leukemia (AML) and the Immune Microenvironment Suppresses Adaptive Immunity

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, bioRxiv.

Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2011 .

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS

S. Kambhampati, N. Daver, G. Ramsingh, 2022, Clinical lymphoma, myeloma & leukemia.

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Naveen Garg, Catherine J. Wu, P. Sharma, 2022, Blood advances.

Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.

M. Konopleva, G. Garcia-Manero, T. Kadia, 2021, American journal of hematology.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, Blood Cancer Journal.

Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2013 .

Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia

M. Konopleva, H. Kantarjian, T. Kadia, 2019, Blood.

Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML

M. Konopleva, M. Andreeff, H. Kantarjian, 2021, Blood.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, American journal of hematology.

Central Nervous System Involvement in Blastic Plasmacytoid Dendritic Cell Neoplasm.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

M. Konopleva, H. Kantarjian, A. Lane, 2020 .

Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.

M. Konopleva, H. Kantarjian, J. Cortes, 2018 .

Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.

G. Garcia-Manero, P. Scheinberg, N. Daver, 2023, Blood.

Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML.

P. Sharma, M. Konopleva, M. Andreeff, 2017 .

A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS)

Hui Yang, Simona Colla, Xuelin Huang, 2016 .

Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myelofibrosis

P. Hari, S. Parmar, S. Verstovsek, 2019, Blood.

Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2012 .

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, Blood Cancer Journal.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia

D. Marin, E. Shpall, N. Daver, 2022, Blood.

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Leukemia.

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A Phase II Study of Azacitidine, Venetoclax and Trametinib in Relapsed/Refractory AML Harboring a Ras Pathway-Activating Mutation

M. Konopleva, H. Kantarjian, T. Kadia, 2021, Blood.

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

P. Sharma, M. Konopleva, M. Andreeff, 2020 .

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Xiaoping Su, K. Bhalla, T. Kadia, 2023, Blood cancer journal.

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Cancer.

The role of therapy in the outcome of patients with myelofibrosis

Z. Estrov, H. Kantarjian, S. Verstovsek, 2023, Cancer.

Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014 .

Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors

G. Garcia-Manero, J. Cortes, T. Kadia, 2022, American journal of hematology.

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

T. Mendoza, S. Faiz, M. Godoy, 2023, The oncologist.

Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.

N. Daver, L. Lyle, 2018, American Journal of Managed Care.

Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

M. Konopleva, K. Bhalla, H. Kantarjian, 2023, Haematologica.

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff, G. Garcia-Manero, J. Cortes, 2023, Journal of Hematology & Oncology.

AML-513 The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34).

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Clinical lymphoma, myeloma & leukemia.

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

N. Daver, M. Levis, J. Altman, 2021 .

HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study

N. Daver, C. Jung, M. Arellano, 2020 .

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

M. Konopleva, H. Kantarjian, T. Kadia, 2020 .

HM43239, a Novel Potent Small Molecule FLT3 Inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1 /2 Study

K. Seo, N. Daver, C. Jung, 2019, Blood.

Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations

M. Konopleva, M. Andreeff, H. Kantarjian, 2018, Blood.

Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.

Dhanashree S. Kelkar, N. Daver, S. Joshi, 2004, The Journal of the Association of Physicians of India.

Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

M. Konopleva, M. Andreeff, H. Kantarjian, 2023, Blood advances.

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

J. Welch, M. Konopleva, M. Andreeff, 2019, Blood.

Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2017 .

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020, American journal of hematology/oncology.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016 .

Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia

P. Sharma, M. Konopleva, Z. Estrov, 2017 .

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

A Randomized Phase II Trial of 5-Day Versus 10-Day Schedules of Decitabine for Older Patients with Previously Untreated Acute Myeloid Leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2017 .

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

M. Konopleva, G. Garcia-Manero, T. Kadia, 2022, Blood.

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Blood advances.

A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-Naïve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2021, Blood.

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

M. Konopleva, H. Kantarjian, E. Shpall, 2023, Blood advances.

Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

K. Bhalla, G. Garcia-Manero, T. Kadia, 2022, Blood.

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2021, Leukemia.

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2020 .

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

R. Bejar, O. Abdel-Wahab, P. Greenberg, 2022, Blood advances.

Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Bifid liver in a patient with diaphragmatic hernia.

N. Daver, G. Bakhshi, Mohit J. Jain, 2005, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia

P. Sharma, M. Konopleva, M. Andreeff, 2018, Cancer.

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Tae Kon Kim, R. Bejar, O. Abdel-Wahab, 2023, Blood reviews.

era: analysis of patient from six trials.

P. Jain, F. Ravandi, G. Borthakur, 2016 .

A Single Case of Rosai–Dorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine

D. Podoloff, G. Borthakur, N. Daver, 2014, Front. Oncol..

Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia.

N. Daver, M. Yilmaz, 2023, The Lancet. Haematology.

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

M. Konopleva, M. Andreeff, H. Kantarjian, 2016 .

Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS).

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, Journal of Clinical Oncology.

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

M. Konopleva, M. Andreeff, N. Daver, 2021, Blood.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

G. Garcia-Manero, K. Patel, G. Borthakur, 2022, Blood.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Editorial: The Biological Landscape of Immunotherapy in AML

N. Daver, A. Curti, A. Isidori, 2021, Frontiers in Oncology.

Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

M. Konopleva, M. Andreeff, G. Garcia-Manero, 2022, Blood.

Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2018, Blood.

A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, Blood.

Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, British journal of haematology.

A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, European journal of cancer care.

Philadelphia–positive dimorphic blasts in mixed‐phenotype acute leukemia with TET2 mutation

Z. Estrov, P. Jain, N. Daver, 2016, American journal of hematology.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations

K. Bhalla, H. Kantarjian, G. Garcia-Manero, 2021, Frontiers in Oncology.

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

P. Sharma, J. Allison, H. Kantarjian, 2018, Leukemia.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, Haematologica.

Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.

M. Konopleva, Z. Estrov, H. Kantarjian, 2018, The Lancet. Haematology.

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015, Leukemia & lymphoma.

Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies

J. Issa, H. Kantarjian, E. Jabbour, 2016 .

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016 .

Clinical outcomes in adult patients with aplastic anemia: A single institution experience

S. Parmar, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

Nature of Clinical Response and Depth of Molecular Response in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Treated with Magrolimab with Azacitidine

P. Vyas, N. Daver, Yajia Zhang, 2022, Blood.

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

K. Spiekermann, N. Daver, M. Subklewe, 2022, Blood.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

M. Konopleva, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)

M. Konopleva, Z. Estrov, M. Andreeff, 2011 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2020 .

A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2020 .

Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS

Jianhua Zhang, H. Kantarjian, G. Garcia-Manero, 2015 .

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2023, Blood.

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

P. Vyas, M. Konopleva, H. Kantarjian, 2023, Blood cancer discovery.

Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2022, American journal of hematology.

The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels

M. Konopleva, H. Kantarjian, T. Kadia, 2021 .

Novel immunotherapies in the treatment of AML: is there hope?

N. Daver, D. Sallman, Marion Subklewe, 2023, Hematology. American Society of Hematology. Education Program.

5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs)

M. Konopleva, Z. Estrov, H. Kantarjian, 2015 .

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Blood.

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2023, Blood.

P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA

S. Kornblau, M. Andreeff, F. Ravandi, 2022, HemaSphere.

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

M. Konopleva, M. Andreeff, N. Daver, 2021, Blood.

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium

Xingmin Feng, N. Daver, L. Adès, 2024, HemaSphere.

8 Immune correlates associated with clinical outcomes in patients with advanced malignancies treated with avelumab and OX40 agonist

Fei Yang, I. Wistuba, F. Meric-Bernstam, 2020 .

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

A. Malovannaya, Xiaoping Su, K. Bhalla, 2023, bioRxiv.